505(b)(2) means A new drug application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. in FDA
Similar to 505(b)(2)
ADE/ADER - Adverse Drug Experience/Adverse Drug Experience ReportADEC - Australian Drug Evaluation Committee
AdEERS - Adverse Event Expidited Reporting System NCI
ADH - antidiuretic hormone
ADI - acceptable daily intake
ADME - absorption, distribution, metabolism, and excretion
ADMIA (CBER) - Associate Director for Medical and International Affairs CBER
View all in FDA